Recombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech)

重组抗HER2人源化单抗偶联美登素衍生物DM1（海正药业/天广实生物）

Report date: 2024/02/05 13:54:57

Base Information

Drug NameRecombinant anti-HER2 human monoclonal antibody-DM1 (Hisun Pharm/Mabworks Biotech)
Drug Alias Name注射用重组抗HER2人源化单抗偶联美登素衍生物DM1HS-630HS630
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linker > MCC linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > DM1 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)
Mechanisms of ActionTubulin polymerisation inhibitorsAnti-HER2Tubulin inhibitors
TargetsTubulinReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsBreast Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhejiang Hisun Pharmaceutical Co LtdBeijing Mabworks Biotech Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhejiang Hisun Pharmaceutical Co LtdBeijing Mabworks Biotech Co LtdHisun Pharmaceutical (Hangzhou) Co Ltd
Inactive CompaniesN/A
Active IndicationsBreast Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A